During the corresponding time, Coherus Oncology Inc recorded a revenue increase by 39.53 % year on year, sequentially revenue grew by 16.22 %. While revenue at the Coherus Oncology Inc 's corporate clients
Coherus Oncology Inc's Comment on Sales, Marketing and Customers
The company has licensed products to Vaccinex, which holds worldwide rights to develop, manufacture, and commercialize these products, with milestone payments and royalties contingent on clinical and regulatory achievements. Under the GSK Agreement, the company granted GSK an exclusive license to develop, manufacture, and commercialize antibodies targeting PVRIG, including GSK4381562. GSK was responsible for all related costs and activities until the agreement's termination in December 2025. The company received a $30 million milestone payment from GSK in March 2022. Additionally, the company entered a Canada License Agreement with Apotex, granting Apotex exclusive rights to commercialize toripalimab in Canada. Apotex made an upfront payment and agreed to milestone payments and royalties on net sales. Apotex received Health Canada approval for LOQTORZI to treat recurrent unresectable or metastatic nasopharyngeal cancer in October 2025, with first commercial sales beginning in January 2026. The agreement term extends ten years after first sales, with an option for a ten-year extension, and Apotex may terminate the agreement under certain conditions. Customers and markets referenced include Apotex, GSK, Junshi Biosciences, and Vaccinex.
In the ever-evolving landscape of cancer immunotherapy, the latest data unveiled by Coherus Oncology at the Society for Immunotherapy of Cancer (SITC) conference highlights a promising leap forward in precision medicine. CHS-114, a groundbreaking anti-CCR8 cytolytic antibody, demonstrates significant potential in altering the immune microenvironment of head and neck squamous cell carcinoma (HNSCC). As the pharmaceutical industry continues to invest in immunotherapeutic innovations, CHS-114 stands out by targeting and depleting regulatory T cells (Tregs) within the tumor milieu, thus paving the way for improved patient outcomes.CCR8, or C-C chemokine receptor type 8, is prominently expressed on the surface of...
Coherus Biosciences, a biopharmaceutical company focused on the development of innovative immunotherapies, has recently made significant strides in the field of oncology. During the upcoming American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO-GI) 2025, the company is set to present final Phase 2 results from its clinical studies on casdozokitug, a first-in-class IL-27-targeted antibody. This study evaluates the efficacy of casdozokitug in combination with toripalimab and bevacizumab in treating patients with metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer.The Phase 2 randomized study aims to ascertain the clinical outcomes of this combination therapy,...
Coherus s Innovative Antibodies Show Potential in the Treatment of Cancer: A Closer Look at CHS-114, LOQTORZI, and CasdozokitugThe field of oncology is constantly evolving, with new therapeutic options emerging to combat various types of cancer. Coherus, a leading biopharmaceutical company, has recently presented promising results from three clinical studies at key medical conferences. These studies focused on their antibodies CHS-114, LOQTORZI, and Casdozokitug, which have shown remarkable efficacy and safety profiles in the treatment of solid tumors and nasopharyngeal cancer. This article will explore the significance of these findings and their potential implications for future cancer therapies.Promising ...
Coherus BioSciences, Inc. has recently announced a new clinical collaboration with the Cancer Research Institute (CRI) for evaluating a novel combination therapy for the treatment of ovarian cancer. The collaboration will focus on studying LOQTORZI (toripalimab-tpzi), an anti-PD-1 antibody, in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR).The selection of LOQTORZI by the CRI s Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee highlights the potential of this drug combination in combating drug-resistant cancers. The IPROC platform study aims to identify innovative treatment options for pati...
Coherus Presents Promising Data for CHS-1000, a Novel Anti-ILT4 Antibody, at 2024 AACR Annual MeetingCoherus BioSciences, a leading biotechnology company, recently presented encouraging preclinical data for their groundbreaking product candidate, CHS-1000, at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The preclinical studies have demonstrated the high affinity of CHS-1000 for human ILT4, showing remarkable potential in reversing ILT4-mediated immunosuppressive functions. This breakthrough mechanism has the potential to enhance antitumor responses in cancer patients undergoing immunotherapy.One of the major challenges in cancer treatment is the evasion of the immune system by tum...
Coherus Announces Revolutionary Breakthrough: LOQTORZI Positioned as the Ultimate First-Line Treatment for Nasopharyngeal Cancer In a groundbreaking revelation, Coherus Biosciences Inc. unveiled the updated position of LOQTORZI (toripalimab-tpzi) in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. This cutting-edge immunotherapy has now been designated as the sole Preferred Category 1 regimen for first-line treatment of adults suffering from metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), in combination with chemotherapy. Additionally, LOQTORZI monotherapy has been deemed the only preferred regimen for subsequent lines of therapy. This groundbreaking...
Coherus Oncology Inc’s Comment on Sales, Marketing and Customers
The company has licensed products to Vaccinex, which holds worldwide rights to develop, manufacture, and commercialize these products, with milestone payments and royalties contingent on clinical and regulatory achievements. Under the GSK Agreement, the company granted GSK an exclusive license to develop, manufacture, and commercialize antibodies targeting PVRIG, including GSK4381562. GSK was responsible for all related costs and activities until the agreement's termination in December 2025. The company received a $30 million milestone payment from GSK in March 2022. Additionally, the company entered a Canada License Agreement with Apotex, granting Apotex exclusive rights to commercialize toripalimab in Canada. Apotex made an upfront payment and agreed to milestone payments and royalties on net sales. Apotex received Health Canada approval for LOQTORZI to treat recurrent unresectable or metastatic nasopharyngeal cancer in October 2025, with first commercial sales beginning in January 2026. The agreement term extends ten years after first sales, with an option for a ten-year extension, and Apotex may terminate the agreement under certain conditions. Customers and markets referenced include Apotex, GSK, Junshi Biosciences, and Vaccinex.
Sources:
Coherus Oncology inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Coherus Oncology inc’s corporate clients.
For your research, we’ve provided 9 tables on Coherus Oncology inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
177.65 %